http://www.hopkinsmedicine.org/healthnewsfeed/index.html The Health NewsFeed is a one-minute radio news program on health and medicine produced by the Johns Hopkins Medicine division of Media Relations and Public Affairs. Topical and informative, the Health NewsFeed provides a Johns Hopkins Medicine's expert opinion on breaking medical news as well as showcasing research originating here. Sun, 24 Oct 2010 23:00:00 EST en-us http://www.hopkinsmedicine.org/hnf/hnf/jh1025.mp3 http://www.hopkinsmedicine.org/hnf/hnf/jh1025.mp3 Sun, 24 Oct 2010 23:00:00 EST The carotid arteries are the big blood vessels that supply the head with blood. Sometimes they become clogged, putting someone at risk for stroke, and must be reopened. The best way to do that is a subject of hot debate, with a recent study in the New England Journal of Medicine seeming to conclude that the surgery known as carotid endarterectomy, was best. Alexander Coon, a neurosurgeon at Johns Hopkins, comments. http://www.hopkinsmedicine.org/hnf/hnf/jh1026.mp3 http://www.hopkinsmedicine.org/hnf/hnf/jh1026.mp3 Sun, 24 Oct 2010 23:00:00 EST Rituximab is one of a class of medications called monoclonal antibodies, which are specifically designed to interfere with or modify certain receptors on cells. Rituximab has now proven useful in one type of leukemia, known as chronic lymphocytic leukemia or CLL. William Nelson, director of the Kimmel Cancer Center at Johns Hopkins, describes how these monoclonal antibodies work. http://www.hopkinsmedicine.org/hnf/hnf/jh1027.mp3 http://www.hopkinsmedicine.org/hnf/hnf/jh1027.mp3 Sun, 24 Oct 2010 23:00:00 EST Once cancer of almost any type has spread, or metastasized, it seems there’s little anyone can do. Now there’s hope for advanced prostate cancer with a drug called carbazitaxel, a cousin of a drug called docetaxel that’s been in use for some time. William Nelson, director of the Kimmel Cancer Center at Johns Hopkins, explains. http://www.hopkinsmedicine.org/hnf/hnf/jh1028.mp3 http://www.hopkinsmedicine.org/hnf/hnf/jh1028.mp3 Sun, 24 Oct 2010 23:00:00 EST When ovarian cancer comes back, finding it and treating it early doesn’t seem to prolong survival, a study in the Lancet found. Deborah Armstrong, an ovarian cancer expert at Johns Hopkins, offers her interpretation of the study. http://www.hopkinsmedicine.org/hnf/hnf/jh1029.mp3 http://www.hopkinsmedicine.org/hnf/hnf/jh1029.mp3 Sun, 24 Oct 2010 23:00:00 EST CA125 is a cancer blood marker often used to assess whether ovarian cancer has recurred. A recent study published in the Lancet found that when the marker was used along with additional assessments to detect recurrent disease, and treatment initiated, these patients did not live any longer than those who were treated when symptoms of recurrence appeared. Deborah Armstrong, an ovarian cancer expert at Johns Hopkins, comments.